benign prostatic hyperplasia treatment Market Trends

Growth Drivers

• Spiking cases of urinary tract infection: According to the NLM May 2021, UTIs are common, with an annual US incidence of 12% among women and 3% among men. It further states that the lifetime prevalence of UTI in men is about 12%. Prevalence of UTIs, mainly among the aging male population, is promoting early diagnosis and treatment of underlying BPH conditions. This is boosting the demand for both pharmacological treatments and minimally invasive procedures, accelerating market growth.
• Increasing healthcare expenditure per capita: Improvement in the healthcare infrastructure, followed by the increase in the healthcare expenditure around the world, is upgrading treatment with better technology available for the patients. Therefore, it is expected to surge the growth of the global benign prostatic hyperplasia (BPH) prostate treatment market.

Per Capita Medical Expenses, USD, 2022

Source:Peterson-KFF Health system Tracker

Challenges

• Stringent government regulations regarding the sales and consumption of medicines: Strict approval processes, pricing controls, and compliance requirements can delay product launches and limit the availability of advanced therapies. Additionally, regulatory barriers can increase the overall cost of treatment, affecting patient accessibility, especially in price-sensitive regions.
• Lack of awareness of the disease in developing countries: This hampers early diagnosis and timely treatment significantly. Limited health education, inadequate health healthcare infrastructure and cultural stigma around urological issues prevent many patients from seeking medical attention. This results in underdiagnosis and a lower adoption rate of both pharmacological and surgical treatment options